Eloxx Pharmaceuticals’ Phase 2 Study of ELX-02 in Cystinosis Receives Authorization of Clinical Trial Application (CTA) by Health Canada and Funding from Genome Quebec and Genome Canada June 10, 2019 - NASDAQ Companies 0 » View More News for June 10, 2019